For research use only. Not for use in humans.

Bemarituzumab (Anti-FGFR2 / CD332)

Cat.No.A2497 Purity:99%

Bemarituzumab (Anti-FGFR2 / CD332) is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. MW: 145.24 KD.

Click to purchase the isotype control of Bemarituzumab (Anti-FGFR2 / CD332)

Quality Control

Batch: Purity: 99% Protein concentration: 5.933mg/ml Endotoxin Level: ＜1EU/mg

Specificity

Name	Citation	FGFR	FGFR1	FGFR2	FGFR3	FGFR4	Others
PD173074	124		++				VEGFR2
Dovitinib (TKI-258)	52		+++		+++		FLT3,c-Kit,VEGFR3/FLT4
Fexagratinib (AZD4547)	145		++++	+++	++++		KDR
Danusertib (PHA-739358)	46		++				Aurora A,Abl,TrkA
Brivanib (BMS-540215)	10		+				VEGFR2,Flk1,VEGFR1
ENMD-2076	9		+	+			FLT3,RET,Aurora A
MK-2461	4		+	++	+		c-Met (M1250T),c-Met (Y1235D),c-Met (Y1230H)
Brivanib Alaninate (BMS-582664)	2		+				VEGFR2,Flk1,VEGFR1
Tyrphostin AG 1296	14	+					PDGFR,c-Kit (Swiss 3T3)
SSR128129E	9		+
Irpagratinib	0					+++
R1530	0		++				VEGFR2
FIIN-3	0		+++	++	++	++
Lucitanib (E3810) hydrochloride	1		++	+			VEGFR1,VEGFR3,VEGFR2
Rogaratinib	0		++++	++++	+++	++++
Sulfatinib	1		++				VEGFR3,VEGFR1,CSF1R
ODM-203	0		+++	++	+++	++	VEGFR3,VEGFR2,VEGFR1
Futibatinib (TAS-120)	16		++++	++++	++++	+++
ASP5878	3		++++	++++	++++	+++
Derazantinib	4		+++	++++	+++	++	RET,DDR2,PDGFRβ
H3B-6527	12					++++
Roblitinib (FGF401)	6					++++
PRN1371	2		++++	++++	+++	++	CSF1R
PD-166866	15		+
Fisogatinib (BLU-554)	10					+++
S49076	1		++	++	++		Met,Mer,Axl
NSC12	2			+			FGF3,FGF8b,FGF22
ON123300	4		++				CDK4/CyclinD1,ARK5,RET
SU5402	24		++				VEGFR2,PDGFRβ
BLU9931	21				+	+++
FIIN-2	5		+++	+++	++	++
Dovitinib (TKI258) Lactate monohydrate	31		+++		+++		FLT3,c-Kit,VEGFR3/FLT4
Zoligratinib (Debio-1347)	12		+++	+++	++	+
LY2874455	15		+++	+++	+++	+++	VEGFR2
Ferulic Acid	6		+	+
Resigratinib	0	✔
Lirafugratinib	0			✔
Masitinib mesylate	0				✔		FAK,human recombinant c-Kit,LynB
BO-264	0				✔		TACC3
SKLB 610	2			✔			PDGFR,VEGFR2
Alofanib (RPT835)	5			✔
Gambogenic acid	4	✔					EZH2

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description	Bemarituzumab (Anti-FGFR2 / CD332) is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. MW: 145.24 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1952272-74-0
Molecular Weight	145.24 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.